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Background
Children with haematological or autoimmune diseases
(e.g. lupus erythematodes) are prone to acquire avascular
osteonecrosis (AVN) following treatment with high dose
steroids. More than 35% of those with advanced AVN
stages (Marcus/Enneking II and III) fail to respond solely
to core decompression.
Multipotent mesenchymal stromal cells (MSC) are capa-
ble of transforming into various mesenchymal tissues, e.g.
bone. A combination therapy might be of benefit for
those children.
Objective
We aim to show that the regeneration process of osseous
structures is possible by local MSC application for steroid
induced AVN in a child.
Patients and methods
One female patient with leukaemia and steroid induced
AVN of the right knee (Marcus Enneking stage II-III) was
treated with core decompression and local application of
autologous MSC. The healing process was followed by
MRI and CT-scan over a two year period.
Results
No early or late adverse events occurred. Two weeks after
the procedure our patient was pain-free. Follow-up MRIs
on day +72 and +210 showed a slow regress of the initial
bone marrow edema and a continuing regeneration of the
osseous defect. The CT-scan 24 months later documented
the re-ossification of the initial lesion.
Conclusion
Local MSC-application might be a promising treatment
option for advanced steroid induced AVN in children with
haematological or autoimmune diseases. Results of a pro-
spective study are under preparation.
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